U.S. markets closed
  • S&P 500

    4,471.37
    +33.11 (+0.75%)
     
  • Dow 30

    35,294.76
    +382.20 (+1.09%)
     
  • Nasdaq

    14,897.34
    +73.91 (+0.50%)
     
  • Russell 2000

    2,265.65
    -8.52 (-0.37%)
     
  • Crude Oil

    82.66
    +1.35 (+1.66%)
     
  • Gold

    1,768.10
    -29.80 (-1.66%)
     
  • Silver

    23.35
    -0.13 (-0.54%)
     
  • EUR/USD

    1.1606
    +0.0005 (+0.05%)
     
  • 10-Yr Bond

    1.5760
    +0.0570 (+3.75%)
     
  • GBP/USD

    1.3751
    +0.0074 (+0.54%)
     
  • USD/JPY

    114.2000
    +0.5230 (+0.46%)
     
  • BTC-USD

    60,737.27
    -245.08 (-0.40%)
     
  • CMC Crypto 200

    1,464.06
    +57.32 (+4.07%)
     
  • FTSE 100

    7,234.03
    +26.32 (+0.37%)
     
  • Nikkei 225

    29,068.63
    +517.70 (+1.81%)
     

Novartis' Prostate Cancer Therapy Linked To Improved Quality Of Life

  • Oops!
    Something went wrong.
    Please try again later.
·1 min read
In this article:
  • Oops!
    Something went wrong.
    Please try again later.
  • Novartis AG (NYSE: NVS) is building the case for its radioligand therapy, 177Lu-PSMA-617.

  • With positive Phase 3 primary endpoint data in the bag, Novartis at the European Society of Medical Oncology Congress 2021 (ESMO21) presented the therapy's effect on the quality of life and pain.

  • Earlier this year, Novartis revealed that the Phase 3 trial linked 177Lu-PSMA-617 to a four-month median improvement in overall survival.

  • Related Link: Novartis' Prostate Cancer Radioligand Therapy Extended Overall Survival by Four Months.

  • Novartis sought to understand the effect of 177Lu-PSMA-617 on daily activities through secondary endpoints that looked at the patient-reported quality of life and pain.

  • The endpoints linked the drug to estimated risk reductions in the worsening of health-related quality of life and pain intensity of 54% and 55%, respectively.

  • Read Next: Novartis Beefs Up Radioligand Portfolio With iTheranostics Deal.

  • The company is ramping up other studies that could enable it to bring 177Lu-PSMA-617 to more prostate cancer patients.

  • In one study, Novartis is enrolling men who are yet to take taxanes, a class of chemotherapy drugs.

  • The other ongoing trial could move 177Lu-PSMA-617 into an even line of treatment by testing it in combination with standard of care.

  • Price Action: NVS stock closed 0.82% lower at $84.38 on Thursday.

  • Check out our coverage of the European Society for Medical Oncology Congress (ESMO21).

See more from Benzinga

© 2021 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.